Researcher
Peter Vandenberghe
- Disciplines:Genetics, Systems biology, Medical imaging and therapy, Molecular and cell biology, Other paramedical sciences
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Responsible
From1 Jan 2008 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → Today
Projects
1 - 10 of 19
- Establishing an evidence ecosystem for blood donation deferral criteria in men who have sex with menFrom9 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Map, Join and Drive European Activities for Advanced Therapy Medicinal Product Development and Implementation for Patient and Society BenefitFrom1 Jan 2024 → TodayFunding: Horizon Europe - Health
- PhD project to identify the immune signature after CAR T-cells treatment.From5 Nov 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
- In-depth investigation of patient immune signature after CD19 CAR T-cell therapyFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Integrated PK/PM Model-based Medication Dosing Assist App(lication) in KlinischWerkStation (KWS). Validation Studies of Tacrolimus in (Solid) Organ TransplantationFrom1 Jan 2021 → 31 Dec 2023Funding: IOF - technology validation in lab
- Mechanisms and Diagnosis of Mast Cell and Basophil Activation in Rare Hypersensitivity DisordersFrom1 Nov 2020 → TodayFunding: BOF - doctoral mandates
- Tracking Multiple Myeloma by low-pass sequencing of circulating cell free DNAFrom1 Mar 2019 → 1 Mar 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Circulating cell-free DNA as an alternative gateway to the genetic features of multiple myeloma and as a surrogate marker for disease burden in multiple myeloma.From1 Mar 2019 → 29 Feb 2024Funding: Nonprofit institution or equivalents
- Circulating cell-free DNA: a novel gateway to the genome of Hodgkin/Reed-Sternberg cells in Hodgkin Lymphoma?From1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 229
- Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2(2019)
Authors: Mart Bittremieux, Rita La Rovere, Myriam Baes, Ann Janssens, Peter Vandenberghe, Humbert De Smedt, Jan Parys, Geert Bultynck
Pages: 531 - 547 - Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery(2019)
Authors: Peter Vandenberghe, Jan Cools
Pages: 712 - 725 - Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma(2019)
Authors: Anne Uyttebroeck, Thomas Tousseyn, Peter Vandenberghe
Pages: E17 - E20 - Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors(2019)
Authors: Liesbeth Lenaerts, Peter Vandenberghe, Nathalie Brison, Huiwen Che, Magali Verheecke, Charlotte Maggen, Barbara Dewaele, Steven Vanderschueren, Daan Dierickx, Vincent Vandecaveye, et al.
Pages: 85 - 95 - Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single-center experience and systematic review(2018)
Authors: Steffen Fieuws, Ina Jochmans, Yves Debaveye, Johan Maertens, Peter Vandenberghe, Wim Laleman, Schalk Van der Merwe, Chris Verslype, David Cassiman, Patrick Ferdinande, et al.
Pages: 3007 - 3020 - Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients(2018)
Authors: Laurien De Roeck, Lucienne Michaux, Koen Debackere, Peter Vandenberghe, Timothy Devos
Pages: 785 - 792 - ZUMA-7: RANDOMIZED PHASE 3 ESSAY OF AXICABTAGEN CILOLEUCEL (AXI-CEL) VS STANDARD TREATMENT (SOC) IN PATIENTS WITH LYMPHOMA B DIFFUSE OF LARGE CELLS IN RECYCLED/REFRACTORY (R/R DLBCL)(2018)
Authors: Peter Vandenberghe
Pages: 359 - 359 - Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases(2018)
Authors: Lukas Marcelis, Charlien Berghen, Alexandra De Zutter, Peter Vandenberghe, Gregor Verhoef, Olivier Gheysens, Xavier Sagaert, Daan Dierickx, Thomas Tousseyn
Pages: 1457 - 1469 - Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive(2018)
Authors: Peter Vandenberghe
Pages: 4115 - 4131 - Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study(2018)
Authors: Helena Claerhout, Thomas Tousseyn, Olivier Gheysens, Peter Vandenberghe, Daan Dierickx, Nancy Boeckx
Pages: 603 - 612